Horizon Therapeutics Public Limited (NASDAQ:HZNP) Stock Holdings Lifted by SevenOneSeven Capital Management

SevenOneSeven Capital Management grew its stake in Horizon Therapeutics Public Limited (NASDAQ:HZNP) by 31.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,172 shares of the biopharmaceutical company’s stock after buying an additional 756 shares during the period. SevenOneSeven Capital Management’s holdings in Horizon Therapeutics Public were worth $297,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Quadrant Capital Group LLC lifted its position in shares of Horizon Therapeutics Public by 44.6% during the 2nd quarter. Quadrant Capital Group LLC now owns 350 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 108 shares during the last quarter. Intrust Bank NA increased its stake in Horizon Therapeutics Public by 0.7% during the second quarter. Intrust Bank NA now owns 17,495 shares of the biopharmaceutical company’s stock valued at $1,638,000 after acquiring an additional 124 shares during the period. CIBC World Markets Inc. grew its stake in shares of Horizon Therapeutics Public by 1.4% in the 2nd quarter. CIBC World Markets Inc. now owns 15,065 shares of the biopharmaceutical company’s stock valued at $1,411,000 after purchasing an additional 201 shares during the period. FDx Advisors Inc. grew its stake in shares of Horizon Therapeutics Public by 1.3% in the 2nd quarter. FDx Advisors Inc. now owns 15,754 shares of the biopharmaceutical company’s stock valued at $1,475,000 after purchasing an additional 202 shares during the period. Finally, Cim LLC grew its position in Horizon Therapeutics Public by 1.6% during the 2nd quarter. Cim LLC now owns 13,031 shares of the biopharmaceutical company’s stock worth $1,381,000 after acquiring an additional 202 shares during the last quarter. 87.90% of the stock is owned by institutional investors.

Several research firms have issued reports on HZNP. Jefferies Financial Group began coverage on Horizon Therapeutics Public in a report on Wednesday. They set a “buy” rating and a $132.00 price objective on the stock. Zacks Investment Research raised Horizon Therapeutics Public from a “sell” rating to a “hold” rating and set a $108.00 price objective on the stock in a report on Thursday, July 29th. The Goldman Sachs Group increased their price target on Horizon Therapeutics Public from $96.00 to $107.00 and gave the company a “neutral” rating in a research note on Tuesday, August 24th. Morgan Stanley increased their price target on Horizon Therapeutics Public from $103.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday, August 26th. Finally, Citigroup increased their price target on Horizon Therapeutics Public from $117.00 to $121.00 and gave the company a “buy” rating in a research note on Thursday, August 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $118.82.

HZNP stock traded down $0.51 during trading hours on Thursday, reaching $114.35. 10,196 shares of the stock were exchanged, compared to its average volume of 1,555,958. The firm’s 50-day moving average is $108.63 and its 200-day moving average is $98.64. The company has a market cap of $25.83 billion, a price-to-earnings ratio of 51.05, a PEG ratio of 1.56 and a beta of 1.08. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.55 and a quick ratio of 2.25. Horizon Therapeutics Public Limited has a 12 month low of $66.41 and a 12 month high of $116.34.

Horizon Therapeutics Public (NASDAQ:HZNP) last released its earnings results on Tuesday, August 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.75. The firm had revenue of $832.55 million during the quarter, compared to analysts’ expectations of $697.69 million. Horizon Therapeutics Public had a return on equity of 27.41% and a net margin of 20.27%. The company’s revenue was up 79.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.40 EPS. As a group, equities research analysts forecast that Horizon Therapeutics Public Limited will post 4.35 earnings per share for the current year.

In other news, CEO Timothy P. Walbert sold 50,000 shares of the firm’s stock in a transaction dated Thursday, September 30th. The stock was sold at an average price of $110.30, for a total value of $5,515,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey W. Sherman sold 46,271 shares of the firm’s stock in a transaction dated Tuesday, September 21st. The shares were sold at an average price of $110.00, for a total transaction of $5,089,810.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 185,206 shares of company stock valued at $19,994,717. Corporate insiders own 3.20% of the company’s stock.

Horizon Therapeutics Public Profile

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.

Read More: Day Trading – Risk Worth the Reward?

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.